Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06874894
Enrolling by invitation Observational

Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)

NCT06874894 · tracked via the Priya Life Science South Korea tracker
Sponsor
Chung-Ang University Hospital
Phase
Observational
Started
2022-05-25
Last updated
2025-12-29

Condition(s) studied

Fibrillation, Atrial

Study summary

This study was design to investigate the efficacy and safety of NOAC therapy in Koreans

Eligibility

Sex
ALL
Min age
18 Months
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment. * Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months) * Adults aged 18 or above who have provided consent for clinical information Exclusion Criteria: * Patients with moderate or severe mitral stenosis or mechanical prosthetic valve

Primary outcome measure(s)

  • Clinical ischemic and hemorrhagic events — 12 months
    The Rate of Ischemic stroke, systemic embolism, or myocardial infarction and ISTH (International Society on Thrombosis and Hemostasis) major/minor bleeding events

Trial sites (2)

FacilityCityRegionStatus
Chung-Ang University Gwangmyeong Hospital Gwangmyeong South Korea
Chung-Ang University Hospital Seoul South Korea

More Chung-Ang University Hospital trials in South Korea

12-mm Partial Covered Versus Bare Self-Expandable Metallic Stents for Malignant Distal Biliary Obstruction Recruiting
Transcatheter Arterial Embolization Using Nexsphere-F for Chronic Shoulder Pain Refractory to Conservative Treatment Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06874894 on ClinicalTrials.gov ↗ ← All trials in South Korea